Kiniksa Pharmaceuticals LtdNASDAQ:KNSA
- LAST PRICE24.9900
- TODAY'S CHANGE (%)-0.0100 (-0.0400%)
- Bid / Lots24.1500/ 1
- Ask / Lots26.8500/ 1
- Open / Previous Close25.1300 / 25.0000
- Day Range
- 52 Week Range
- Volume368,700
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KNSA |
|---|---|---|
| 09:32 ET | 3944 | 25.07 |
| 09:34 ET | 744 | 25.1421 |
| 09:38 ET | 100 | 25.1 |
| 09:39 ET | 3511 | 25.145 |
| 09:41 ET | 2665 | 25.06 |
| 09:43 ET | 865 | 25.025 |
| 09:45 ET | 300 | 24.94 |
| 09:48 ET | 876 | 24.955 |
| 09:50 ET | 100 | 24.9 |
| 09:56 ET | 200 | 25.05 |
| 09:57 ET | 1431 | 25.15 |
| 09:59 ET | 1102 | 25.03 |
| 10:01 ET | 176 | 25.04 |
| 10:03 ET | 406 | 25.04 |
| 10:06 ET | 600 | 25.04 |
| 10:08 ET | 700 | 25.13 |
| 10:10 ET | 10560 | 25.31 |
| 10:12 ET | 6596 | 25.225 |
| 10:15 ET | 3270 | 25.205 |
| 10:17 ET | 400 | 25.17 |
| 10:21 ET | 1636 | 25.12 |
| 10:24 ET | 700 | 25.16 |
| 10:32 ET | 200 | 25.16 |
| 10:33 ET | 300 | 25.21 |
| 10:39 ET | 300 | 25.24 |
| 10:44 ET | 100 | 25.27 |
| 10:46 ET | 100 | 25.26 |
| 10:48 ET | 200 | 25.26 |
| 10:50 ET | 600 | 25.265 |
| 10:51 ET | 1500 | 25.27 |
| 10:53 ET | 500 | 25.3 |
| 10:55 ET | 200 | 25.29 |
| 10:57 ET | 900 | 25.19 |
| 11:02 ET | 150 | 25.18 |
| 11:08 ET | 500 | 25.22 |
| 11:11 ET | 1400 | 25.2 |
| 11:13 ET | 100 | 25.23 |
| 11:15 ET | 879 | 25.225 |
| 11:18 ET | 400 | 25.24 |
| 11:20 ET | 100 | 25.2 |
| 11:22 ET | 100 | 25.215 |
| 11:26 ET | 500 | 25.24 |
| 11:27 ET | 900 | 25.17 |
| 11:29 ET | 1165 | 25.155 |
| 11:31 ET | 300 | 25.12 |
| 11:33 ET | 200 | 25.09 |
| 11:36 ET | 4210 | 25.1 |
| 11:38 ET | 300 | 25.12 |
| 11:40 ET | 600 | 25.12 |
| 11:42 ET | 600 | 25.1 |
| 11:44 ET | 8076 | 24.97 |
| 11:47 ET | 100 | 24.96 |
| 11:49 ET | 200 | 24.9675 |
| 11:51 ET | 300 | 24.97 |
| 11:54 ET | 300 | 24.99 |
| 11:56 ET | 360 | 24.99 |
| 12:00 ET | 500 | 25 |
| 12:02 ET | 200 | 25.01 |
| 12:03 ET | 802 | 24.96 |
| 12:05 ET | 500 | 24.99 |
| 12:09 ET | 100 | 24.95 |
| 12:14 ET | 150 | 24.97 |
| 12:16 ET | 4541 | 25 |
| 12:20 ET | 400 | 25 |
| 12:23 ET | 1344 | 25.055 |
| 12:32 ET | 400 | 25.08 |
| 12:34 ET | 11487 | 25.26 |
| 12:36 ET | 900 | 25.265 |
| 12:38 ET | 1000 | 25.285 |
| 12:39 ET | 1115 | 25.275 |
| 12:41 ET | 4960 | 25.235 |
| 12:43 ET | 900 | 25.255 |
| 12:48 ET | 100 | 25.2665 |
| 12:52 ET | 100 | 25.235 |
| 12:54 ET | 200 | 25.24 |
| 12:57 ET | 800 | 25.24 |
| 01:01 ET | 2100 | 25.22 |
| 01:03 ET | 3100 | 25.145 |
| 01:06 ET | 100 | 25.165 |
| 01:10 ET | 1100 | 25.235 |
| 01:12 ET | 300 | 25.21 |
| 01:14 ET | 180 | 25.27 |
| 01:15 ET | 100 | 25.26 |
| 01:17 ET | 300 | 25.24 |
| 01:19 ET | 1000 | 25.22 |
| 01:21 ET | 300 | 25.258 |
| 01:28 ET | 400 | 25.255 |
| 01:30 ET | 1100 | 25.16 |
| 01:32 ET | 700 | 25.12 |
| 01:35 ET | 700 | 25.17 |
| 01:37 ET | 100 | 25.13 |
| 01:39 ET | 100 | 25.18 |
| 01:42 ET | 200 | 25.18 |
| 01:50 ET | 100 | 25.19 |
| 01:51 ET | 300 | 25.2 |
| 01:53 ET | 1219 | 25.22 |
| 01:55 ET | 400 | 25.2285 |
| 01:57 ET | 1901 | 25.215 |
| 02:04 ET | 3794 | 25.14 |
| 02:08 ET | 917 | 24.93 |
| 02:09 ET | 300 | 24.925 |
| 02:11 ET | 136 | 24.9352 |
| 02:13 ET | 600 | 24.88 |
| 02:15 ET | 700 | 24.76 |
| 02:18 ET | 200 | 24.79 |
| 02:20 ET | 100 | 24.79 |
| 02:22 ET | 200 | 24.79 |
| 02:24 ET | 200 | 24.78 |
| 02:26 ET | 1300 | 24.7 |
| 02:27 ET | 100 | 24.715 |
| 02:29 ET | 521 | 24.755 |
| 02:31 ET | 200 | 24.755 |
| 02:33 ET | 600 | 24.74 |
| 02:36 ET | 979 | 24.7176 |
| 02:38 ET | 900 | 24.785 |
| 02:40 ET | 100 | 24.81 |
| 02:44 ET | 800 | 24.88 |
| 02:45 ET | 100 | 24.94 |
| 02:49 ET | 100 | 25 |
| 02:54 ET | 100 | 24.945 |
| 03:00 ET | 100 | 24.97 |
| 03:02 ET | 1011 | 24.86 |
| 03:03 ET | 100 | 24.895 |
| 03:05 ET | 200 | 24.9 |
| 03:14 ET | 304 | 24.87 |
| 03:16 ET | 300 | 24.76 |
| 03:18 ET | 600 | 24.78 |
| 03:20 ET | 200 | 24.81 |
| 03:21 ET | 5100 | 24.93 |
| 03:23 ET | 600 | 24.9 |
| 03:27 ET | 300 | 24.96 |
| 03:30 ET | 864 | 24.96 |
| 03:32 ET | 905 | 24.92 |
| 03:34 ET | 600 | 24.885 |
| 03:36 ET | 100 | 24.915 |
| 03:38 ET | 100 | 24.93 |
| 03:41 ET | 714 | 24.94 |
| 03:43 ET | 200 | 24.93 |
| 03:48 ET | 400 | 24.95 |
| 03:50 ET | 1112 | 24.965 |
| 03:52 ET | 1200 | 24.97 |
| 03:54 ET | 200 | 24.99 |
| 03:56 ET | 2570 | 24.98 |
| 03:57 ET | 1700 | 24.99 |
| 03:59 ET | 103682 | 24.99 |
Sep 13, 2024
DJ Kiniksa Pharmaceuticals Initiated at Buy by Jefferies, from 9:15AM ET on Friday Sep 13, 2024 by Dow Jones
9:15AM ET on Friday Sep 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.8B | -139.7x | --- |
Zai Lab Ltd | 2.1B | -7.9x | --- |
CareDx Inc | 1.5B | -10.4x | --- |
Maravai LifeSciences Holdings Inc | 2.1B | -8.3x | --- |
MannKind Corp | 1.7B | 175.4x | --- |
BioCryst Pharmaceuticals Inc | 1.6B | -10.4x | --- |
Company Information
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Contact Information
- Headquarters
- Clarendon House, 2 Church StreetHAMILTON, Bermuda HM11
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Sanjiv Patel
- Chief Financial Officer, Senior Vice President
- Mark Ragosa
- Chief Operating Officer, Senior Vice President
- Eben Tessari
- Senior Vice President, Chief Commercial Officer
- Ross Moat
- Senior Vice President, Chief Medical Officer
- John Paolini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.8B |
|---|---|
Revenue (TTM) | $338.9M |
Shares Outstanding | 71.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.32 |
EPS | $-0.18 |
Book Value | $6.23 |
P/E Ratio | -139.7x |
Price/Sales (TTM) | 5.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
